Logo

Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar

Share this

Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar

Shots:

  • Genentech filed a complaint in the Eastern District of Texas alleging that the proposed biosimilar to Avastin (bevacizumab) product infringes 10 US patents
  • Genentech alleges that Centus and partners failed to disclose sufficient information about the proposed biosimilar to enable Genentech to do a sufficient analysis of potential patent infringements
  • Centus has a BLA under review with the FDA for the bevacizumab biosimilar candidate FKB238- and the company has filed a notice of intent to commercialize the agent

Click here ­to­ read full press release/ article | Ref: BigMoleculeWatch | Image: Genentech


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions